You are here

Discovery of novel CDK4/6-PI3K-BRD4 inhibitor SRX3177 for augmented anti-cancer activity

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41CA232779-01
Agency Tracking Number: R41CA232779
Amount: $299,738.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: 102
Solicitation Number: PA17-303
Solicitation Year: 2017
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-08-20
Award End Date (Contract End Date): 2019-07-31
Small Business Information
San Diego, CA 92130-4051
United States
DUNS: 078516096
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (520) 336-7477
Business Contact
Phone: (808) 365-4124
Research Institution
9500 Gilman Drive, Mail Code 0934
LA JOLLA, CA 92093-0934
United States

 Nonprofit College or University

Three CDKinhibitors were recently approved to treat breast cancerBrCAin combination regimentsDespite significant clinical activitytreatment of BrCA patients with these combinations does not result in a
durable responseHencethere is an unmet medical need to develop targeted therapeutic agents which will
augment the activity of CDKinhibitors in BrCA and other CDKcyclin D Myc dependent malignanciesA
recent report demonstrated that PIkinasePI Kinhibition is critical to maintain CDKsensitivity of tumor
cellsHenceour central hypothesis to be tested in this proposal is that combined triple inhibition of CDKPI K and BRDwith one small moleculeSRXwill be more efficacious and less toxic than combining
three separate inhibitorsAn innovative component of our proposal is that we have developed in silico
guiding models to design and then synthesized SRXthe first small molecule inhibitory chemotype that
potently inhibits these three important targetsCDKPIK and BRDsimultaneously in the same cellpreliminary resultsWe have demonstratedproof of conceptthat SRXinhibits all three targets at
nM potencyinhibits all three targets in cell based assaysdisplaysfold greater efficacy in cell based
assays for ICdeterminationdisplaysfold less toxicity in normal cellsand most importantlydemonstrates efficacy but lacks detectable toxicity in vivo as compared to the high mortality rate observed in
mice treated withseparate drugs of equal potencye gPalbociclibCDKBKMPI Kand JQBRDThe significance of our proposal lies in our capacity to provide an optimizable promising single
anticancer agent which will potently inhibit CDKCyclin D and Myc via multiple orthogonal signaling
mechanisms and inhibit survival signaling by blocking the PI K pathwayThis proposal will evaluate this
approach by achieving the following aims setting the stage for phase II efforts to optimize the expected triple
inhibitory lead compound sto a clinical candidateAimTaskDevelop a potent CDKinhibitor with
inhibitory properties against PI K and BRDApproachIn silico design and modeling ofchemotypes
to selectSRXanalogsAimTaskCharacterize thenew compoundsApproachDetermine
their CDKBRDand PI K inhibition profiles and ADME propertiesAimTaskDemonstrate triple
inhibitor is superior to use of three separate inhibitors in vivoApproachCompare toxicity and efficacy of
triple inhibitors versus individual CDKPI KBRDinhibitory conditions in vitro and in vivoThe
significance of this research is it will greatly expand the efficacy of CDKinhibition against cyclin D Myc
dependent malignant diseasesThis innovative approach attacks cancer blocking three distinctcancer driving
orthogonal mechanisms with a single compound with greater safety in vivo challenging the one drug one target
dogma Project Narrative
The planned research is relevant to public health because data we and others have acquired shows that our
proposed development of a potent novel CDKPIkinase BRDtrivalent inhibitor to target cancer with
dependency on CDKand PI KMoreoverthe proposal is designed to produce a platform technology for
the development of dual or triple valent small molecule inhibitors of PI K combined with inhibitors of other
targetsthereby having a broad impact on public healthThus the proposed research which will involve a close
collaboration between academia and industry is relevant to the part of the NIH s mission that pertains to the
development of new therapeutics able to reduce the burden of human disability via improved treatment of adult
and childhood cancer

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government